← ANALYST RATINGS · TIPRANKS
Anika Therapeutics (ANIK): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $23.00, the highest $23.00, the lowest $23.00. The average is +15.1% from the last price of $19.98.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $23.00 → $20.00−13.0% | Hold | +0.1% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| Michael Petusky★★★★★★★★★★#4246 · hits 45% · avg +2.3% | Barrington | $21.00 → $23.00+9.5% | Buy | +15.1% | Reiterated | 01.10.26on TipRanks 10:35 | −1.7%next day −2.1% · 5 days −2.0% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $21.00 → $23.00+9.5% | Buy | +15.1% | Initiated | 18.09.26on TipRanks 08:10 | −1.2%next day −2.1% · 5 days −3.4% | ↗ |
| AI xAi Medical - SpecialtiesxAI Grok-4 | TipRanks - xAI | $23.00 | Hold | +15.1% | Reiterated | 28.08.26on TipRanks Aug 27 23:06 | — | |
| AI DeepSeek Medical - SpecialtiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.50 | Hold | +12.6% | Reiterated | 28.08.26on TipRanks Aug 27 23:06 | — | |
| AI OpenAI Medical - SpecialtiesOpenAI 5.2 | TipRanks - OpenAI | $23.00 | Hold | +15.1% | Reiterated | 28.08.26on TipRanks Aug 27 23:06 | — | |
| AI Anthropic Medical - SpecialtiesAnthropic Opus-4.6 | TipRanks - Anthropic | $22.00 | Hold | +10.1% | Reiterated | 28.08.26on TipRanks Aug 27 23:06 | — | |
| AI Google Medical - SpecialtiesGemini 3.1Pro | TipRanks - Google | $23.50 | Hold | +17.6% | Reiterated | 28.08.26on TipRanks Aug 27 23:06 | — | |
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $21.50 → $23.00+7.0% | Hold | +15.1% | Reiterated | 20.08.26on TipRanks Aug 19 23:06 | — | |
| Michael Petusky★★★★★★★★★★#4246 · hits 45% · avg +2.3% | Barrington | $17.00 → $21.00+23.5% | Buy | +5.1% | Reiterated | 30.07.26on TipRanks 07:45 | +10.1%next day +6.0% · 5 days +7.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Anika Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $23.00 at a price of $19.66 (+17.0%); now: $23.00 at $19.98 (+15.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 2 | 2 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.42 (from $0.42 to $0.42). Last quarter: $0.42.
Sales
Next quarter’s sales estimate — $29M (from $29M to $30M). Last quarter: $33M.
Best top-analyst consensus in the sector · Healthcare
About Anika Therapeutics
- CEO: Stephen D. Griffin
- Employees: 235
- 32 Wiggins Avenue, Bedford, MA, 01730, US
- www.anika.com
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Data from the stock’s TipRanks forecast page, read 194 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗